DekaBank Deutsche Girozentrale’s Arcutis Biotherapeutics ARQT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-140,000	Closed	-$1.46M	–	1127
2025 Q4	$1.46M	Hold	140,000	–	–	﹤0.01%	815
2025 Q3	$1.45M	Hold	140,000	–	–	﹤0.01%	810
2025 Q2	$1.46M	Hold	140,000	–	–	﹤0.01%	801
2025 Q1	$1.34M	Hold	140,000	–	–	﹤0.01%	799
2024 Q4	$1.27M	Hold	140,000	–	–	﹤0.01%	828
2024 Q3	$1.34M	Hold	140,000	–	–	﹤0.01%	833
2024 Q2	$1.34M	Hold	140,000	–	–	﹤0.01%	831
2024 Q1	$1.34M	Hold	140,000	–	–	﹤0.01%	821
2023 Q4	$462K	Buy	+140,000	New	+$381K	﹤0.01%	1055
2023 Q2	–	Sell	-30,000	Closed	-$327K	–	1256
2023 Q1	$327K	Hold	30,000	–	–	﹤0.01%	1110
2022 Q4	$438K	Hold	30,000	–	–	﹤0.01%	1066
2022 Q3	$565K	Buy	30,000 +16,000	+114%	+$363K	﹤0.01%	1016
2022 Q2	$310K	Hold	14,000	–	–	﹤0.01%	1114
2022 Q1	$262K	Buy	14,000 +1,300	+10%	+$22K	﹤0.01%	1164
2021 Q4	$260K	Buy	12,700 +300	+2%	+$5.97K	﹤0.01%	1225
2021 Q3	$280K	Hold	12,400	–	–	﹤0.01%	1144
2021 Q2	$320K	Hold	12,400	–	–	﹤0.01%	1135
2021 Q1	$334K	Hold	12,400	–	–	﹤0.01%	1094
2020 Q4	$358K	Buy	+12,400	New	+$304K	﹤0.01%	1091

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ARQT Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 140,000 shares — an estimated $1.46M sold.

DekaBank Deutsche Girozentrale first reported a position in ARQT in Q4 2020 and held it in 19 quarters. The position peaked at $1.46M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 140,000 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.46M.
DekaBank Deutsche Girozentrale first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 19 quarters.
DekaBank Deutsche Girozentrale's Arcutis Biotherapeutics position peaked at $1.46M in Q4 2025.
270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.